ART Announces Launch of SoftScan(R) Clinical Study At Massachusetts General Hospital.MONTREAL -- ART Advanced Research Technologies Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :ART) ("ART"), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that a SoftScan(R) clinical study is now underway at the first of its clinical research sites in the United States, Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world (MGH MGH Massachusetts General Hospital MGH McGraw-Hill Companies MGH Montreal General Hospital (Montreal, Canada) MGH Monumenta Germania Historica MGH May Go Home MGH Minneapolis General Hospital ), in Boston, MA. Led by Dr. Daniel B. Kopans, Director of Breast Imaging at the Massachusetts General Hospital, and a leading authority on breast cancer screening This article or section recently underwent a major revision or rewrite and needs further review. You can help! X-ray mammography Mammography is still the modality of choice for screening of early breast cancer, since it is relatively fast, reasonably accurate, and , this clinical study will provide results to be used by ART in its submission to the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to support the Company's SoftScan Pre-Market Approval ("PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy ") application. "This is an important milestone for our Company, a critical step to bringing the SoftScan breast imaging device to market, and we are honoured to be associated with such a prestigious clinical research site. With the addition of this site, we now have a total of three clinical study sites participating in our clinical trials for SoftScan," declared Mrs. Micheline Bouchard, ART's President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "We are eager to begin imaging patients in this trial. Early detection using mammography has reduced the death rate from breast cancer, but mammography is not perfect. We hope that optical imaging will be able to help us to further reduce the deaths from these cancers," indicated Dr. Daniel B. Kopans, Director of Breast Imaging at the Massachusetts General Hospital. "We also hope to prove that the SoftScan optical imaging system can improve our ability to diagnose breast cancers," he added. Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. , and conducts the largest hospital-based research program in the United States. Further clinical research sites will be announced in late 2005 for additional pivotal studies, which ART plans to conduct in Canada and the United States The United States and Canada share a unique legal relationship. U.S. law looks northward with a mixture of optimism and cooperation, viewing Canada as an integral part of U.S. economic and environmental policy. . About ART ART Advanced Research Technologies Inc. is a leader in optical molecular imaging products for the healthcare and pharmaceutical industries. ART has developed two products based on its innovative technology. The first is eXplore Optix(TM), a molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs. eXplore Optix(TM) is distributed by GE Healthcare and is used by industry and academic leaders worldwide to bring new and better treatments to patients faster. The second is SoftScan(R), a medical imaging device designed to improve the diagnosis and treatment of breast cancer. ART is commercializing its products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. Visit ART online at www.art.ca This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART Advanced Research Technologies Inc.'s regulatory filings with Canadian Securities Commissions and the Securities and Exchange Commission in the United States. ART Advanced Research Technologies Inc. (TSX:ARA) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion